KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Expenses: 2013-2024

Historic Accumulated Expenses for Teva Pharmaceutical Industries (TEVA) over the last 12 years, with Dec 2024 value amounting to $624.0 million.

  • Teva Pharmaceutical Industries' Accumulated Expenses fell 9.37% to $561.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $561.0 million, marking a year-over-year decrease of 9.37%. This contributed to the annual value of $624.0 million for FY2024, which is 2.13% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Accumulated Expenses of $624.0 million as of FY2024, which was up 2.13% from $611.0 million recorded in FY2023.
  • Teva Pharmaceutical Industries' Accumulated Expenses' 5-year high stood at $685.0 million during FY2020, with a 5-year trough of $563.0 million in FY2021.
  • In the last 3 years, Teva Pharmaceutical Industries' Accumulated Expenses had a median value of $611.0 million in 2023 and averaged $600.3 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Accumulated Expenses dropped by 17.81% in 2021, and later climbed by 7.95% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Accumulated Expenses (Yearly) stood at $685.0 million in 2020, then fell by 17.81% to $563.0 million in 2021, then rose by 0.53% to $566.0 million in 2022, then grew by 7.95% to $611.0 million in 2023, then rose by 2.13% to $624.0 million in 2024.